Cargando…

Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses

Binding of pattern recognition receptors (PRRs) by pathogen-associated molecular patterns (PAMPs) activates innate immune responses and contributes to development of adaptive immunity. Simultaneous stimulation of different types of PRRs can have synergistic immunostimulatory effects resulting in enh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tukhvatulin, Amir I., Dzharullaeva, Alina S., Tukhvatulina, Natalia M., Shcheblyakov, Dmitry V., Shmarov, Maxim M., Dolzhikova, Inna V., Stanhope-Baker, Patricia, Naroditsky, Boris S., Gudkov, Andrei V., Logunov, Denis Y., Gintsburg, Alexander L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871337/ https://www.ncbi.nlm.nih.gov/pubmed/27187797 http://dx.doi.org/10.1371/journal.pone.0155650

Ejemplares similares

NOD1/2 and the C-Type Lectin Receptors Dectin-1 and Mincle Synergistically Enhance Proinflammatory Reactions Both In Vitro and In Vivo
por: Tukhvatulin, Amir I, et al.
Publicado: (2020)

Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice
por: Tukhvatulin, Amir, et al.
Publicado: (2020)

Toll-Like Receptors (TLRs): The Role in Tumor Progression
por: Shcheblyakov, D.V., et al.
Publicado: (2010)

The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector
por: Lebedeva, Ekaterina, et al.
Publicado: (2018)

Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis
por: Burmistrova, Daria A., et al.
Publicado: (2016)

Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein
por: Ozharovskaia, T. A., et al.
Publicado: (2019)

Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa
por: Dzharullaeva, Alina S., et al.
Publicado: (2018)

A In Vitro and In Vivo Study of the Ability of NOD1 Ligands to Activate the Transcriptional Factor NF-kB
por: Tukhvatulin, A.I., et al.
Publicado: (2011)

Virus-Vectored Ebola Vaccines
por: Dolzhikova, I.V., et al.
Publicado: (2017)

Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
por: Voronina, Daria V., et al.
Publicado: (2022)

Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply
por: Logunov, Denis Y, et al.
Publicado: (2021)

Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection
por: Koroleva, Ekaterina A., et al.
Publicado: (2017)

Triggering of Toll-like Receptor-2 in Mouse Myelomonocytic Leukaemia Cells WEHI-3B Leads to the Suppression of Apoptosis and Promotes Tumor Progression in Vivo
por: Shcheblyakov, D.V., et al.
Publicado: (2011)

Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply
por: Logunov, Denis Y, et al.
Publicado: (2020)

Association of Mycoplasma hominis infection with prostate cancer
por: Barykova, Yulia A., et al.
Publicado: (2011)

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
por: Logunov, Denis Y, et al.
Publicado: (2020)

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
por: Dolzhikova, I. V., et al.
Publicado: (2017)

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
por: Tukhvatulin, Amir I., et al.
Publicado: (2021)

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
por: Logunov, Denis Y, et al.
Publicado: (2021)

Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice
por: Godakova, Svetlana A., et al.
Publicado: (2019)

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
por: Lapa, Daniele, et al.
Publicado: (2022)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
por: Tukhvatulin, Amir I., et al.
Publicado: (2023)

An Efficient Method for the Delivery of the Interleukin-2 Gene to Human Hematopoietic Cells using the  Fiber-Modified Recombinant Adenovirus
por: Rogozhin, V.N., et al.
Publicado: (2011)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
por: Tukhvatulin, Amir I., et al.
Publicado: (2022)

Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts
por: Tutykhina, Irina, et al.
Publicado: (2018)

Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome
por: Dolzhikova, I. V., et al.
Publicado: (2020)

Regulation of the Target Protein (Transgene) Expression in the Adenovirus Vector Using Agonists of Toll-Like Receptors
por: Bagaev, A. V., et al.
Publicado: (2014)

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
por: Esmagambetov, Ilias B., et al.
Publicado: (2023)

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
por: Derkaev, Artem A., et al.
Publicado: (2022)

Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
por: Panova, Eugenia A., et al.
Publicado: (2023)

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant
por: Wei, Jingjing, et al.
Publicado: (2022)

Assessment of the Parameters of Adaptive Cell-Mediated Immunity in Naïve Common Marmosets (Callithrix jacchus)
por: Gordeychuk, I. V., et al.
Publicado: (2018)

Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection
por: Esmagambetov, I. B., et al.
Publicado: (2021)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

Silica-based cationic bilayers as immunoadjuvants
por: Lincopan, Nilton, et al.
Publicado: (2009)

Construction of a pIX-modified Adenovirus Vector Able to Effectively Bind to Nanoantibodies for Targeting
por: Garas, M. N., et al.
Publicado: (2014)

Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer
por: Ghochikyan, Anahit, et al.
Publicado: (2014)

Immunoadjuvant Activity of Fucoidans from the Brown Alga Fucus evanescens
por: Kuznetsova, Tatyana A., et al.
Publicado: (2020)

Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis
por: Cao, Ruoqiong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hpmp0e70ed6js4n1ddn0i94h1k